Duc Binh Phan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duc Binh Phan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Zenas Zee Ngai Yiu
Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester
10 shared publications - Richard B. Warren
Dermatology Centre, Northern Care Alliance NHS Foundation Trust and Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
6 shared publications - Catherine H. Smith
St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust and King's College London London UK
5 shared publications - Heber Rew Bright Bright
Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester
4 shared publications Mark Lunt
Versus Arthritis Epidemiology Unit, University of Manchester , Manchester
4 shared publications- Mark Lunt
Division of Musculoskeletal and Dermatological sciences, University of Manchester , Manchester
4 shared publications
Latest Publications
- 13 November 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Suspected skin cancer referral rates after implementation of a pre-referral artificial intelligence-supported pathway: a synthetic control analysis
This analysis evaluated whether a pre-referral artificial intelligence-supported pathway could reduce urgent suspected skin cancer referrals from primary to secondary care. Using synthetic control methods to compare six pilot GP practices with a matched control based on 30 non-pilot practices, the analysis found no statistically significant reduction in referral rates during the 11-month pilot.
- 13 November 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Suspected skin cancer referral rates after implementation of a pre-referral artificial intelligence-supported pathway: a synthetic control analysis
This analysis evaluated whether a pre-referral artificial intelligence-supported pathway could reduce urgent suspected skin cancer referrals from primary to secondary care. Using synthetic control methods to compare six pilot GP practices with a matched control based on 30 non-pilot practices, the analysis found no statistically significant reduction in referral rates during the 11-month pilot.
- Open Access
- 15 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Risks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data
Background: Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis (TB), meningitis, candidiasis and other fungal infections. However, real-world comparative data including interleukin (IL)-17 and IL-23 inhibitors remain limited. Methods: We conducted a nationwide cohort study using data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death or last available follow-up data. Primary outcomes included TB, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years (PY) were calculated and incidence rate ratios (IRRs) were estimated using a doubly robust interval-based Poisson regression model. An entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. Results: A total of 40 930 treatment episodes from 18 635 patients contributing 118 018 PY of follow-up were included in this analysis. During the follow-up, 22 TB cases, 29 meningitis cases and 888 fungal infection cases, including 450 cases of candidiasis, were reported. The overall incidence rates were 0.18 [95% confidence interval (CI) 0.12–0.28] for TB, 0.25 (95% CI 0.16–0.35) for meningitis and 7.53 (95% CI 7.05–8.05) for fungal infections per 1000 PY. Most TB and meningitis cases were associated with tumour necrosis factor-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and TB was largely pulmonary. Thirty-day mortality was seen in < 5 cases in meningitis. IL-17 inhibitors alone exhibited an increased risk of candidiasis compared with all other systemic treatment groups, with IRRs ranging from 2.67 (95% CI 1.33–5.36) vs. apremilast to 4.65 (95% CI 3.46–6.24) vs. the IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the risk of candidiasis. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. Conclusions: In this large cohort study, TB and meningitis were rare and longer-term follow-up is required to further characterize the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks in patients receiving IL-17 inhibitors.
- 15 September 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Open AccessRisks of tuberculosis, meningitis, candidiasis and fungal infections in patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data
Background: Systemic treatments for psoriasis confer differential risk profiles for infections such as tuberculosis (TB), meningitis, candidiasis and other fungal infections. However, real-world comparative data including interleukin (IL)-17 and IL-23 inhibitors remain limited. Methods: We conducted a nationwide cohort study using data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) from 2007 to 2024. Adults with psoriasis receiving systemic treatments were included and followed from treatment initiation until treatment discontinuation, death or last available follow-up data. Primary outcomes included TB, meningitis, candidiasis and other fungal infections. Incidence rates per 1000 person-years (PY) were calculated and incidence rate ratios (IRRs) were estimated using a doubly robust interval-based Poisson regression model. An entropy balancing method was used to achieve covariate balance across treatment groups and multiple imputation was used to handle missing baseline data. Results: A total of 40 930 treatment episodes from 18 635 patients contributing 118 018 PY of follow-up were included in this analysis. During the follow-up, 22 TB cases, 29 meningitis cases and 888 fungal infection cases, including 450 cases of candidiasis, were reported. The overall incidence rates were 0.18 [95% confidence interval (CI) 0.12–0.28] for TB, 0.25 (95% CI 0.16–0.35) for meningitis and 7.53 (95% CI 7.05–8.05) for fungal infections per 1000 PY. Most TB and meningitis cases were associated with tumour necrosis factor-α inhibitors, particularly adalimumab. Meningitis was predominantly viral and TB was largely pulmonary. Thirty-day mortality was seen in < 5 cases in meningitis. IL-17 inhibitors alone exhibited an increased risk of candidiasis compared with all other systemic treatment groups, with IRRs ranging from 2.67 (95% CI 1.33–5.36) vs. apremilast to 4.65 (95% CI 3.46–6.24) vs. the IL-12/23 inhibitor. Individual IL-17 inhibitors did not exhibit significant differences in the risk of candidiasis. With fungal infections other than candidiasis, no statistically significant differences were observed between treatment groups. Conclusions: In this large cohort study, TB and meningitis were rare and longer-term follow-up is required to further characterize the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks in patients receiving IL-17 inhibitors.
- 8 July 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (10) , 1189-1205
Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods
Objectives Psoriasis is a chronic inflammatory skin condition with a significant cost burden on the UK National Health Service (NHS). The objective of this systematic review is to describe and analyse the methods used in UK-based cost-utility analyses of systemic treatments for psoriasis and psoriatic arthritis. Methods We registered the review protocol on PROSPERO (CRD420251179345). We searched Embase, MEDLINE, EconLit, NHS Economic Evaluations Database, and the websites of UK health technology assessment (HTA) organisations on 1 December 2025 with no language or date restrictions. We also checked the reference lists of previous systematic reviews for additional studies. The review included journal publications and HTA submission documents that reported cost-utility models evaluating systemic treatments for psoriasis or psoriatic arthritis in a UK setting. We conducted a narrative synthesis of modelling methods using all sources of information for each model. We evaluated model quality using the Drummond checklist. Results Searches identified 659 unique, potentially relevant records (databases, n = 582; reference lists, n = 13; HTA websites, n = 64). After screening, we included 68 reports detailing 35 cost-utility analyses (psoriasis, n = 18; psoriatic arthritis, n = 17). Most followed a similar cohort-level model structure with induction and maintenance phases, but approaches to modelling treatment sequences varied and may not reflect clinical practice. Most psoriatic arthritis models accounted for both skin and joint symptoms, but psoriasis models only considered skin symptoms, and neither group directly modelled the impact of other comorbidities. Additional research would be beneficial to better inform parameters for efficacy in sequences of treatment and disease-related costs. The review was limited by incomplete reporting for some models. Conclusions Model structures in psoriasis cost-utility analyses are well-established, but future work should address limitations in approaches to treatment sequencing and comorbidities by better leveraging real-world evidence.
- 8 July 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (10) , 1189-1205
Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods
Objectives Psoriasis is a chronic inflammatory skin condition with a significant cost burden on the UK National Health Service (NHS). The objective of this systematic review is to describe and analyse the methods used in UK-based cost-utility analyses of systemic treatments for psoriasis and psoriatic arthritis. Methods We registered the review protocol on PROSPERO (CRD420251179345). We searched Embase, MEDLINE, EconLit, NHS Economic Evaluations Database, and the websites of UK health technology assessment (HTA) organisations on 1 December 2025 with no language or date restrictions. We also checked the reference lists of previous systematic reviews for additional studies. The review included journal publications and HTA submission documents that reported cost-utility models evaluating systemic treatments for psoriasis or psoriatic arthritis in a UK setting. We conducted a narrative synthesis of modelling methods using all sources of information for each model. We evaluated model quality using the Drummond checklist. Results Searches identified 659 unique, potentially relevant records (databases, n = 582; reference lists, n = 13; HTA websites, n = 64). After screening, we included 68 reports detailing 35 cost-utility analyses (psoriasis, n = 18; psoriatic arthritis, n = 17). Most followed a similar cohort-level model structure with induction and maintenance phases, but approaches to modelling treatment sequences varied and may not reflect clinical practice. Most psoriatic arthritis models accounted for both skin and joint symptoms, but psoriasis models only considered skin symptoms, and neither group directly modelled the impact of other comorbidities. Additional research would be beneficial to better inform parameters for efficacy in sequences of treatment and disease-related costs. The review was limited by incomplete reporting for some models. Conclusions Model structures in psoriasis cost-utility analyses are well-established, but future work should address limitations in approaches to treatment sequencing and comorbidities by better leveraging real-world evidence.
- Open Access
- 5 May 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (2) , 261-269
Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Background: Systemic treatments for psoriasis could increase the risk of serious infection due to their inhibitory effect on the immune system. Objectives: To estimate and compare the serious infection risk associated with systemic treatments for psoriasis Methods: Adult patients with psoriasis who received at least one of the systemic treatments and had 6-month follow-up data recorded in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) database were included in the analysis. Patients were followed from the time of drug initiation to drug discontinuation, death or last available follow-up date. Infections that occurred during or up to 90 days after treatment discontinuation resulting in hospitalization, the administration of intravenous antimicrobials or death were considered serious. Inverse probability of treatment weighting was used to balance baseline covariates. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated using a piece-wise Cox proportional hazards model. A recurrent event analysis was also performed using the Prentice–Williams–Peterson model. Missing data were handled using multiple imputation. Results: In total, 46 770 treatment episodes from 18 976 patients were analysed. Patients were predominantly men (n = 10 893; 57.4%) and had a mean (SD) age of 45.64 (13.67) years and a mean (SD) BMI of 31.60 (7.28) kg m–2. The incidence rate of serious infections was 27.67 events per 1000 person-years (95% CI 26.72–28.65) and the rate of recurrent serious infection in those with prior infection was 78.70 events per 1000 person-years (95% CI 75.17–82.36). The piecewise Cox proportional hazards model showed an increased risk of serious infection with apremilast (HR 1.53, 95% CI 1.27–1.80) and secukinumab (HR 1.34, 95% CI 1.18–1.50) compared with adalimumab. However, these findings were not consistent across sensitivity analyses. The recurrent event analysis showed a lower risk with risankizumab than with brodalumab (HR 0.74, 95% CI 0.55–0.99), etanercept (HR 0.75, 95% CI 0.60–0.94) and standard treatments (HR 0.80, 95% CI 0.65–0.98). Serious infection-associated deaths were rare (incidence rate 1.81 per 1000 person-years, 95% CI 1.57–2.07). Conclusions: Despite isolated signals in the time-to-first event analysis, the more robust recurrent event analysis showed that risankizumab was associated with a lower risk of serious infections, while no significant differences were observed among the other systemic treatments for psoriasis.
- 5 May 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (2) , 261-269
Open AccessSerious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Background: Systemic treatments for psoriasis could increase the risk of serious infection due to their inhibitory effect on the immune system. Objectives: To estimate and compare the serious infection risk associated with systemic treatments for psoriasis Methods: Adult patients with psoriasis who received at least one of the systemic treatments and had 6-month follow-up data recorded in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) database were included in the analysis. Patients were followed from the time of drug initiation to drug discontinuation, death or last available follow-up date. Infections that occurred during or up to 90 days after treatment discontinuation resulting in hospitalization, the administration of intravenous antimicrobials or death were considered serious. Inverse probability of treatment weighting was used to balance baseline covariates. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated using a piece-wise Cox proportional hazards model. A recurrent event analysis was also performed using the Prentice–Williams–Peterson model. Missing data were handled using multiple imputation. Results: In total, 46 770 treatment episodes from 18 976 patients were analysed. Patients were predominantly men (n = 10 893; 57.4%) and had a mean (SD) age of 45.64 (13.67) years and a mean (SD) BMI of 31.60 (7.28) kg m–2. The incidence rate of serious infections was 27.67 events per 1000 person-years (95% CI 26.72–28.65) and the rate of recurrent serious infection in those with prior infection was 78.70 events per 1000 person-years (95% CI 75.17–82.36). The piecewise Cox proportional hazards model showed an increased risk of serious infection with apremilast (HR 1.53, 95% CI 1.27–1.80) and secukinumab (HR 1.34, 95% CI 1.18–1.50) compared with adalimumab. However, these findings were not consistent across sensitivity analyses. The recurrent event analysis showed a lower risk with risankizumab than with brodalumab (HR 0.74, 95% CI 0.55–0.99), etanercept (HR 0.75, 95% CI 0.60–0.94) and standard treatments (HR 0.80, 95% CI 0.65–0.98). Serious infection-associated deaths were rare (incidence rate 1.81 per 1000 person-years, 95% CI 1.57–2.07). Conclusions: Despite isolated signals in the time-to-first event analysis, the more robust recurrent event analysis showed that risankizumab was associated with a lower risk of serious infections, while no significant differences were observed among the other systemic treatments for psoriasis.
- Open Access
- 16 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 58-67
Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register
Background: Current treatment pathways for moderate-to-severe psoriasis in the UK and the Republic of Ireland direct initiation of targeted biologic immunomodulators when conventional systemic drugs are ineffective or not tolerated. Starting biologics early in the treatment pathway may modify disease course and improve short- and long-term outcomes. Objectives: To compare the effectiveness and risk of incident comorbid conditions over 5 years when initiating a biologic as the first systemic treatment vs. the current standard of care, in which the patients started with a conventional non-biologic systemic therapy with possible subsequent switch to biologics. Methods: This study applied the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register. Adults (aged ≥ 18 years) with moderate-to-severe psoriasis [baseline Psoriasis Area and Severity Index (PASI) ≥ 10] and no prior systemic therapy were included. Five-year trajectories of PASI and Dermatology Life Quality Index (DLQI) were modelled using mixed-effects repeated-measures models. The probability of complete skin clearance (PASI 0) and the risk of developing long-term comorbidities (cardiovascular, hepatic, neoplastic, metabolic, mental health or musculoskeletal disorders, and incident psoriatic arthritis) were estimated using marginal structural models with stabilized inverse probability weighting to adjust for baseline and time-varying confounding. Results: We included 3702 patients: 3368 followed the current standard of care and 334 initiated a biologic as first-line systemic therapy. At 5 years, the modelled mean PASI was 4.7 [95% confidence interval (CI) 4.0–5.4] for standard of care and 2.0 (95% CI 1.2–2.7) for biologic initiators; DLQI were 5.6 (95% CI 4.2–7.0) and 3.5 (95% CI 1.3–5.7), respectively. The cumulative rate of achieving PASI 0 was 32.2 vs. 58.6%, with a higher likelihood of PASI 0 for biologic initiators [hazard ratio (HR) 2.85, 95% CI 2.34–3.47]. The cumulative risk of chronic comorbidities was lower among biologic initiators (47.5 vs. 54.3%; HR 0.72, 95% CI 0.58–0.89), with lower risks of mental health (HR 0.64, 95% CI 0.44–0.94) and hepatic (HR 0.54, 95% CI 0.38–0.76) disorders. Conclusions: Initiating biologics as the first systemic therapy was associated with better clinical outcomes compared with standard stepwise approaches. Our results support reconsideration of existing pathways to allow earlier use of biologics.
- 16 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (1) , 58-67
Open AccessUsing biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register
Background: Current treatment pathways for moderate-to-severe psoriasis in the UK and the Republic of Ireland direct initiation of targeted biologic immunomodulators when conventional systemic drugs are ineffective or not tolerated. Starting biologics early in the treatment pathway may modify disease course and improve short- and long-term outcomes. Objectives: To compare the effectiveness and risk of incident comorbid conditions over 5 years when initiating a biologic as the first systemic treatment vs. the current standard of care, in which the patients started with a conventional non-biologic systemic therapy with possible subsequent switch to biologics. Methods: This study applied the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators Register. Adults (aged ≥ 18 years) with moderate-to-severe psoriasis [baseline Psoriasis Area and Severity Index (PASI) ≥ 10] and no prior systemic therapy were included. Five-year trajectories of PASI and Dermatology Life Quality Index (DLQI) were modelled using mixed-effects repeated-measures models. The probability of complete skin clearance (PASI 0) and the risk of developing long-term comorbidities (cardiovascular, hepatic, neoplastic, metabolic, mental health or musculoskeletal disorders, and incident psoriatic arthritis) were estimated using marginal structural models with stabilized inverse probability weighting to adjust for baseline and time-varying confounding. Results: We included 3702 patients: 3368 followed the current standard of care and 334 initiated a biologic as first-line systemic therapy. At 5 years, the modelled mean PASI was 4.7 [95% confidence interval (CI) 4.0–5.4] for standard of care and 2.0 (95% CI 1.2–2.7) for biologic initiators; DLQI were 5.6 (95% CI 4.2–7.0) and 3.5 (95% CI 1.3–5.7), respectively. The cumulative rate of achieving PASI 0 was 32.2 vs. 58.6%, with a higher likelihood of PASI 0 for biologic initiators [hazard ratio (HR) 2.85, 95% CI 2.34–3.47]. The cumulative risk of chronic comorbidities was lower among biologic initiators (47.5 vs. 54.3%; HR 0.72, 95% CI 0.58–0.89), with lower risks of mental health (HR 0.64, 95% CI 0.44–0.94) and hepatic (HR 0.54, 95% CI 0.38–0.76) disorders. Conclusions: Initiating biologics as the first systemic therapy was associated with better clinical outcomes compared with standard stepwise approaches. Our results support reconsideration of existing pathways to allow earlier use of biologics.
- 28 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 964-966
Serious infection risk in people treated with infliximab for severe psoriasis
The risk of serious infection in people with severe psoriasis treated with infliximab was examined in a cohort study using real-world data from BADBIR. The propensity score method and inverse probability of treatment weights were used to balance covariates across treatment groups. An Andersen–Gill recurrent Cox model was used to estimate hazard ratios for comparisons with infliximab. Our findings suggest that infliximab is associated with an increased risk of serious infection vs. adalimumab, secukinumab, ustekinumab and standard treatments.
- 28 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 964-966
Serious infection risk in people treated with infliximab for severe psoriasis
The risk of serious infection in people with severe psoriasis treated with infliximab was examined in a cohort study using real-world data from BADBIR. The propensity score method and inverse probability of treatment weights were used to balance covariates across treatment groups. An Andersen–Gill recurrent Cox model was used to estimate hazard ratios for comparisons with infliximab. Our findings suggest that infliximab is associated with an increased risk of serious infection vs. adalimumab, secukinumab, ustekinumab and standard treatments.
- Open Access
- 31 October 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (1) , 191-204
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence
Introduction Systemic treatments including standard and targeted drugs for psoriasis could increase the risk of serious infections. In this study we assessed the serious infection risk associated with systemic treatments in patients with psoriasis. Methods A systematic review of randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) comparing systemic treatments with placebo or each other was performed. Studies included in Medline, Embase, Cochrane register, CINAHL and ClinicalTrials.gov until September 2024 were eligible if at least 50 adults or children with plaque psoriasis were studied. The primary outcome was serious infection defined as any infection resulting in hospitalization, administration of intravenous antibiotics, death or classified as serious by study authors. Two authors independently performed screening for study eligibility. A frequentist network meta-analysis (NMA) was performed using random effects model. RCT, NRSI and combined (RCT and NRSI) networks were created. Results From 119 eligible RCTs, 76 with at least one serious infection event (n = 39,044) and out of 33 eligible NRSIs, 6 without critical risk of bias (n = 306,762) were included in the NMA. Patients were predominantly male (up to 85%) with a mean age ranging from 13 to 52 years. The RCT network showed no increase in serious infection risk with any drug or drug class when compared with each other. The NRSI network showed higher risk with infliximab and adalimumab compared to several other drugs, especially infliximab vs methotrexate (IRR 2.85; 95% CI 1.48, 5.46), and adalimumab vs ustekinumab (IRR 1.51; 95% CI 1.25, 1.83). In the combined NMA, infliximab and adalimumab were additionally shown to have significantly higher risk than acitretin, bimekizumab, methotrexate, placebo, risankizumab, and secukinumab. Conclusions The tumour necrosis factor alpha (TNFα) inhibitors adalimumab and infliximab had higher risk of serious infections in the combined NMA. Our findings may inform clinicians and patients concerned about the risk of emergent serious infection on therapy.
- 31 October 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (1) , 191-204
Open AccessSerious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence
Introduction Systemic treatments including standard and targeted drugs for psoriasis could increase the risk of serious infections. In this study we assessed the serious infection risk associated with systemic treatments in patients with psoriasis. Methods A systematic review of randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) comparing systemic treatments with placebo or each other was performed. Studies included in Medline, Embase, Cochrane register, CINAHL and ClinicalTrials.gov until September 2024 were eligible if at least 50 adults or children with plaque psoriasis were studied. The primary outcome was serious infection defined as any infection resulting in hospitalization, administration of intravenous antibiotics, death or classified as serious by study authors. Two authors independently performed screening for study eligibility. A frequentist network meta-analysis (NMA) was performed using random effects model. RCT, NRSI and combined (RCT and NRSI) networks were created. Results From 119 eligible RCTs, 76 with at least one serious infection event (n = 39,044) and out of 33 eligible NRSIs, 6 without critical risk of bias (n = 306,762) were included in the NMA. Patients were predominantly male (up to 85%) with a mean age ranging from 13 to 52 years. The RCT network showed no increase in serious infection risk with any drug or drug class when compared with each other. The NRSI network showed higher risk with infliximab and adalimumab compared to several other drugs, especially infliximab vs methotrexate (IRR 2.85; 95% CI 1.48, 5.46), and adalimumab vs ustekinumab (IRR 1.51; 95% CI 1.25, 1.83). In the combined NMA, infliximab and adalimumab were additionally shown to have significantly higher risk than acitretin, bimekizumab, methotrexate, placebo, risankizumab, and secukinumab. Conclusions The tumour necrosis factor alpha (TNFα) inhibitors adalimumab and infliximab had higher risk of serious infections in the combined NMA. Our findings may inform clinicians and patients concerned about the risk of emergent serious infection on therapy.
- 3 March 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (7)
Switching back to originator adalimumab from biosimilars in psoriasis: A cohort study from BADBIR
- 3 March 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (7)
Switching back to originator adalimumab from biosimilars in psoriasis: A cohort study from BADBIR
- Open Access
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
Introduction Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage. Methods and analysis This study aims to compare the drug survival and safety of adalimumab biosimilars to adalimumab originator for the treatment of psoriasis. We will use both routinely collected healthcare databases and dedicated pharmacovigilance registries from the PsoNet initiative, including data from the UK, France and Spain. We will conduct a cohort study using a prevalent new user design. We will match patients on previous adalimumab exposure time to create two equal-sized cohorts of biosimilar and originator users. The coprimary outcomes are drug survival, defined by the time from cohort entry to discontinuation of the drug of interest; and risk of serious adverse events, defined by adverse events leading to hospitalisation or death. Cox proportional hazards models will be fitted to calculate HRs as the effect estimate for the outcomes. Ethics and dissemination The participating registries agree with the Declaration of Helsinki and received approval from local ethics committees. The results of the study will be published in scientific journals and presented at international dermatology conferences by the end of 2023.
Open AccessDrug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
Introduction Psoriasis is a chronic inflammatory skin disease. Adalimumab is an effective but previously expensive biological treatment for psoriasis. The introduction of biosimilars following the patent expiry of the originator adalimumab Humira has reduced the unit cost of treatment. However, the long-term effectiveness and safety of adalimumab biosimilars for treating psoriasis in real-world settings are uncertain and may be a barrier to widespread usage. Methods and analysis This study aims to compare the drug survival and safety of adalimumab biosimilars to adalimumab originator for the treatment of psoriasis. We will use both routinely collected healthcare databases and dedicated pharmacovigilance registries from the PsoNet initiative, including data from the UK, France and Spain. We will conduct a cohort study using a prevalent new user design. We will match patients on previous adalimumab exposure time to create two equal-sized cohorts of biosimilar and originator users. The coprimary outcomes are drug survival, defined by the time from cohort entry to discontinuation of the drug of interest; and risk of serious adverse events, defined by adverse events leading to hospitalisation or death. Cox proportional hazards models will be fitted to calculate HRs as the effect estimate for the outcomes. Ethics and dissemination The participating registries agree with the Declaration of Helsinki and received approval from local ethics committees. The results of the study will be published in scientific journals and presented at international dermatology conferences by the end of 2023.
- Open Access
- 5 April 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (1) , 62-70
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Background: Tumour necrosis factor-alpha inhibitors (TNFi) have revolutionized the treatment of moderate-to-severe psoriasis. Following patent expiry of the originator biologics, TNFi biosimilars became available, presenting the opportunity for significant reductions in drug costs. Objectives: To describe the uptake of TNFi biosimilars for psoriasis treatment in the UK and Ireland. Methods: This observational cohort study utilizes data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), a national pharmacovigilance study register for patients with psoriasis on systemic treatments. We analysed biosimilar uptake trends over time in nine geographical regions of England along with Wales, Scotland, Northern Ireland and the Republic of Ireland. We assessed the incidence of switching to biosimilars in an originator-user cohort (switchers). Patients on originators infliximab, etanercept and adalimumab at the time originator patents expired, entered the cohort on 1 February 2015, August 2015 and October 2018, respectively, and were followed up until 31 October 2021. Trends in biosimilar initiations were assessed in an adalimumab-naïve cohort who started adalimumab between 1 October 2018 and 31 July 2019 (starters). We assessed the associations between patient factors and originator-to-biosimilar switching and biosimilar initiation using a multivariable Cox regression model and a multivariable logistic regression model, respectively. Results: Included in the originator-user cohort were 4202 patients (209 on infliximab, 742 on etanercept and 3251 on adalimumab). For infliximab, etanercept and adalimumab, respectively, the cumulative incidence of originator-to-biosimilar switching increased with time to 14.8%, 23.6% and 66.6% after 3 years. Across geographical regions, 3-year switching rates varied from 0% to 43.7% for infliximab; from 0% to 40.4% for etanercept; and from 12.5% to 84.3% for adalimumab. Out of the 528 patients included in the adalimumab-naïve cohort, 67.8% started on biosimilars. Originator-to-biosimilar switching and biosimilar initiation were more common in men and in patients who had lower Psoriasis Area and Severity Index at cohort entry. Conclusions: The uptake of biosimilars increased over time and varied considerably across the UK and Ireland; adalimumab had the highest biosimilar uptake rate compared with that of other TNFi drugs.
- 5 April 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (1) , 62-70
Open AccessUptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Background: Tumour necrosis factor-alpha inhibitors (TNFi) have revolutionized the treatment of moderate-to-severe psoriasis. Following patent expiry of the originator biologics, TNFi biosimilars became available, presenting the opportunity for significant reductions in drug costs. Objectives: To describe the uptake of TNFi biosimilars for psoriasis treatment in the UK and Ireland. Methods: This observational cohort study utilizes data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), a national pharmacovigilance study register for patients with psoriasis on systemic treatments. We analysed biosimilar uptake trends over time in nine geographical regions of England along with Wales, Scotland, Northern Ireland and the Republic of Ireland. We assessed the incidence of switching to biosimilars in an originator-user cohort (switchers). Patients on originators infliximab, etanercept and adalimumab at the time originator patents expired, entered the cohort on 1 February 2015, August 2015 and October 2018, respectively, and were followed up until 31 October 2021. Trends in biosimilar initiations were assessed in an adalimumab-naïve cohort who started adalimumab between 1 October 2018 and 31 July 2019 (starters). We assessed the associations between patient factors and originator-to-biosimilar switching and biosimilar initiation using a multivariable Cox regression model and a multivariable logistic regression model, respectively. Results: Included in the originator-user cohort were 4202 patients (209 on infliximab, 742 on etanercept and 3251 on adalimumab). For infliximab, etanercept and adalimumab, respectively, the cumulative incidence of originator-to-biosimilar switching increased with time to 14.8%, 23.6% and 66.6% after 3 years. Across geographical regions, 3-year switching rates varied from 0% to 43.7% for infliximab; from 0% to 40.4% for etanercept; and from 12.5% to 84.3% for adalimumab. Out of the 528 patients included in the adalimumab-naïve cohort, 67.8% started on biosimilars. Originator-to-biosimilar switching and biosimilar initiation were more common in men and in patients who had lower Psoriasis Area and Severity Index at cohort entry. Conclusions: The uptake of biosimilars increased over time and varied considerably across the UK and Ireland; adalimumab had the highest biosimilar uptake rate compared with that of other TNFi drugs.